Pre-frontal cortex processing disorder speech, gait and limb impairments treatment
AssigneeGilrose Pharmaceuticals, LLC
InventorsBruce Roseman, Gilla Kaplan
Life of this patent
Estimating the term…
Abstract
A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a subject to treat a speech, gait or limb impairment secondary to a genetically acquired pre-frontal cortex processing disease or disorder, particularly including multiple sclerosis, cerebral palsy, Angelman syndrome, Rett syndrome and Fragile-X syndrome.
Claims16
A combination of pharmaceutical interventions (a) and (b) for treating a pre-frontal cortex processing neurological disease or disorder having a secondary speech, gait or limb impairment, wherein
- (a) comprises THIP or an analog;
- and
- (b) comprises a pharmaceutical intervention treating the secondary impairment, and wherein (b) comprises a lower alkyl phenidate;
- whereby the disease or disorder is treated and the impairment is diminished, and wherein the disease or disorder comprises cerebral palsy (CP).
A method for treating a pre-frontal cortex processing disorder and simultaneously treating a gait or limb impairment secondary to the disorder, said method comprises administering to a subject in need of such treatment;
- (a) THIP or an analog;
- and
- (b) a norepinephrine dopamine reuptake inhibitor (NDRI);
- whereby the disorder is treated and the gait or limb impairment is simultaneously diminished.
Dependencies are inferred from the claim text.